Amoxapine
A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.
Khối lượng phân tử
313,8000 g/mol
LogP
2,60
TPSA
36,90 Ų
Lipinski RO5
Đạt
Cơ chế tác dụng
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
InChI
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
Molecular Formula
C17H16ClN3O
HBD / HBA
1 / 3
Liên kết có thể quay
1
Nguyên tử nặng
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Amoxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1113. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2170. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amoxapine"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amoxapine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amoxapine/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amoxapine/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amoxapine"></drugfyi-drug>